Contact Us
Press Center

Company News

Your current location: Home>Press Center >Company News
 

TOT BIOPHARM Introduces New Strategic Shareholders

[Palo Alto, California, USA; Taipei and Suzhou News] TOT BIOPHARM COMPANY LTD., a privately held biopharmaceutical company dedicated to developing anti-cancer therapeutics, today announced the company has completed the closing of new strategic shareholders. The investment is led by Vivo Capital with participation by Formosa Laboratories, Inc. joined by existing investors Center Laboratories Group and Chengwei Capital. This investment has acquired all shares originally held by TTY Biopharm Co. Ltd, and the transaction amount was roughly USD24 million.

Vivo Capital, who led the investment, will leverage its network and experience in healthcare in both China and the U.S. and facilitate strategic alliances including cross-border partnerships, recruit new management, and introduction of new products in order to accelerate the development of TOT BIOPHARM. Meanwhile, the new investor, Formosa Laboratories, Inc., will use its advantages in bulk pharmaceutical chemical production and manufacturing to further strengthen cooperation with TOT BIOPHARM.

Vivo Capital, who led the investment, will leverage its network and experience in healthcare in both China and the U.S. and facilitate strategic alliances including cross-border partnerships, recruit new management, and introduction of new products in order to accelerate the development of TOT BIOPHARM. Meanwhile, the new investor, Formosa Laboratories, Inc., will use its advantages in bulk pharmaceutical chemical production and manufacturing to further strengthen cooperation with TOT BIOPHARM.

About TOT BIOPHARM

TOT BIOPHARM Co., Ltd. (http://www.totbiopharm.cn/) was established in Suzhou Industrial Park in 2010 as a biomedical company focused on anti-cancer therapeutics. TOT BIOPHARM has used mainland China as its base for new drug research and development, manufacturing, and marketing, but it has established clinical test platforms throughout Asia in order to expand its global market operations. Currently, eleven product line projects are in research, five projects have been declared China IND projects, and seven independent patents have been acquired.

The core technology platform of the company is as follows:

(1) Biological drugs (including biosimilar, those represented by therapeutic monoclonal antibodies, new protein drugs, etc.)

(2) Innovative biotech drugs (including oncolytic virus, oncogene, and tumor immunotherapy drugs)

(3) Drugs with special dosage forms (generally using nanotechnology, with further development and application of drugs with new dosage forms)

A “Balance between Humanities and Science and Technology” is the operation philosophy of TOT BIOPHARM, which insists on starting from the general demand of cancer patients and aims at overall “people-oriented” care. By doing so, the cancer patients can apply the optimal anti-cancer drugs at a suitable anti-cancer time. The company emphasizes individualized medical treatment and integral rehabilitation from cancer. “Achieving good health for the body-mind-spirit of cancer patients” is the ultimate value of TOT BIOPHARM with regard to the anti-cancer business.

About Vivo Capital

Vivo Capital (http://vivocapital.com) is a healthcare focused investment firm formed in 1996 with over $1.7 billion under management into promising private and public healthcare companies in the U.S. and greater China. Vivo employs a unique multi-pronged strategy of identifying and working with companies with promising development stage and commercial stage therapeutic products in the U.S. and revenue stage companies in China. Vivo Capital has offices in Palo Alto, California, Taipei, Shanghai, Chengdu, and Beijing, China.

About Formosa Laboratories, Inc

Formosa Laboratories, Inc. (http://www.formosalab.com/) was established in 1995 through the establishment of a research and development laboratory and entered the field of bulk pharmaceutical chemical production in 2000. With powerful research and development strength and a solid quality system, it has gradually flourished within the biotechnology and pharmaceutical industry. It is currently marketing more than 30 active pharmaceutical ingredients and sun care active ingredients around the world. Furthermore, it possesses ISO certification and has been successfully certified by TFDA, the U.S. FDA, Germany’s BGV, the European Union EDQM, Japan’s PMDA, and Mexico’s COFEPRIS.

Contact TOT BIOPHARM

Joy Chen

Director, General Manager’s Office

+886 2 2655-8399 ext 6908

joy@totbiopharm.com